The BMJ Interview - Andrew Pollard on the Oxford/Astra Zeneca vaccine
Andrew Pollard is Director of the Oxford Vaccines Group - who, along with Astra Zeneca, have developed an modified adenovirus vaccine for SARS-CoV-2.
In this interview we talk to him about the development of that vaccine - what he thinks about the UK government's plan to increase the interval between doses; if he worries about a mutating virus and vaccine escape; and how the university came to make a deal with a commercial company to provide co st-price vaccinations for the world.www.bmj.com/coronavirus
Source: The BMJ Podcast - Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
More News: Adenoviruses | AstraZeneca | Coronavirus | COVID-19 | General Medicine | Government | Podcasts | SARS | Vaccines